Actively Recruiting
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Led by Neurocrine Biosciences · Updated on 2026-04-15
284
Participants Needed
11
Research Sites
116 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
CONDITIONS
Official Title
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant has a primary diagnosis of schizophrenia
- Participant is experiencing an acute exacerbation or relapse of symptoms and currently warrants hospitalization
- Participants taking prohibited medications, including antipsychotics, must discontinue before study participation
- Participant is willing and able to remain in an inpatient setting for the study duration, follow instructions, and comply with the protocol requirements
- Participant is between 18 and 65 years old
You will not qualify if you...
- Participant has known hypersensitivity to any component of the formulation of NBI-1117568
- Participant has an unstable or poorly controlled medical condition or chronic disease
- Participant is considered by the investigator to be at imminent risk of suicide or injury to self or others
- Participant has a diagnosis of moderate or severe substance use disorder (except nicotine or caffeine dependence) within 6 months prior to screening
- Participant has a positive alcohol test or drug screen for disallowed substances
- Participant has a history of poor or suspected poor compliance in clinical research studies or is not capable of adhering to the protocol requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Neurocrine Clinical Site
Culver City, California, United States, 90230
Actively Recruiting
2
Neurocrine Clinical Site
Garden Grove, California, United States, 92845
Actively Recruiting
3
Neurocrine Clinical Site
Riverside, California, United States, 92506
Actively Recruiting
4
Neurocrine Clinical Site
Atlanta, Georgia, United States, 30328
Actively Recruiting
5
Neurocrine Clinical Site
North Canton, Ohio, United States, 44720
Actively Recruiting
6
Neurocrine Clinical Site
Sliven, Bulgaria, 8800
Actively Recruiting
7
Neurocrine Clinical Site
Veliko Tarnovo, Bulgaria, 5047
Withdrawn
8
Neurocrine Clinical Site
Vratsa, Bulgaria, 3001
Actively Recruiting
9
Neurocrine Clinical Site
Brasov, Romania, 500123
Actively Recruiting
10
Neurocrine Clinical Site
Brasov, Romania, 507190
Actively Recruiting
11
Neurocrine Clinical Site
Bucharest, Romania, 41914
Actively Recruiting
Research Team
N
Neurocrine Medical Information Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here